--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO ...

AMVUTTRA® (vutrisiran) product logo ATTR-CM is a devastating ... Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals, Inc.ALNY entered into an exclusive agreement with Israel's leading pharmaceuticals partner, Medison Pharma to commercialize its newly approved RNAi therapeutic Onpattro in ...

This is the first demonstration of gene silencing by RNAi therapeutics in the human brain using Alnylam's proprietary C16 platform. The findings represent a significant milestone not only for ...

the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. The agreement between Alnylam and Medison includes ...

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna ...

In contrast, Alnylam is one biotech company which is tipped to deliver on huge expectations, thanks to a rigorous approach to validating its science – RNA interference (RNAi) - a technology ...

Alnylam has been extremely persistent over the years in getting their RNA interference ideas developed and tested. That original RNAi therapy (patisiran) was directed towards neuropathy ...

− Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today’s Patients – – Only Therapeutic Approved in the U.S ...

CAMBRIDGE, Mass., March 20, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA ...